

# Long-Term Outcomes After Successful Treatment of TTP

Spero R. Cataland, M.D.  
Assoc. Professor of Clinical Internal  
Medicine  
Division of Hematology  
Ohio State University



# Historical Perspective

- Prior to PEX therapy nearly uniformly fatal
- Rock et al in 1991
  - PEX superior to plasma infusion
    - Mortality 10-20%
- Increasing numbers of survivors
  - Able to now evaluate for long-term issues

# What Took So Long?

- Continuity of care
  - Referral back to local hematologist
  - Not followed
    - Normal platelet count, normal patient
- Longitudinal follow-up of patients
  - Emphasis of research programs
- TTP patient group meetings
  - University of Oklahoma

# Neurocognitive Deficits and TTP

## *Oklahoma TTP-HUS Registry*

- 24 patients with previous history of TTP
  - ADAMTS13 <10% at presentation
  - Normal physical exam
  - Normal MMSE
    - Screening for dementia




# Neurocognitive Deficits and TTP

## *Oklahoma TTP-HUS Registry*

- Significantly worse as a group on 4/11 cognitive domains tested
  - Complex attention/concentration skills
  - Information processing speed
  - Rapid language generation
  - Rote memorization
    - 21/24 (88%) below expectations on at least 1/11 domains tested
- Not predictive: age, features of TTP, multiple episodes, interval from last episode

# Data Collection Scheme



# Neurocognitive Function Testing

## CogState® Neurocognitive Test Battery


- Computerized, self-administered, rapid testing system
- Large reference dataset from normal population
- Established validity and utility for detection of disease- and drug-related neurocognitive impairment
  
- Detection Task – psychomotor function / speed
- Identification – attention / vigilance
- One Card Learning – visual learning & memory
- One Back Memory – working memory
- Groton Maze Learning Test – executive function

# Prevalence of Neurocognitive Deficits

- 31% (9/29) unable to complete test of executive function (GMLT), no score imputed
- 62% (18/29) patients  $<1$  SD below age-matched norm on at least 1 of the 4 other tests
- 52% (15/29) scored  $<2$  SD below age-matched norm on at least 1 of the 4 other tests
- 45% (13/29) patients  $<1$  SD below age-matched norm on at least 2 of the 4 other tests



# Comparison of Neurocognitive Deficits in Differing Disease States



# Correlations Among Measures Of CNS Injury

Neurocognitive (NC) deficits and MRI evidence of structural damage:

- 15/29 patients with NC impairment
  - 7 of these 15 also have abnormal MRI
- 9/23 patients with abnormal MRI
  - 7 of these 9 also have NC impairment
- NC testing may be more sensitive than MRI for detection of CNS injury in TMA

## Long-term, sub-clinical cardiac and renal complications in patients with multiple relapses of thrombotic thrombocytopenic purpura

- At presentation
  - 17/22 (77%) with proteinuria
  - 15/22 (68%) had increased serum creatinine
- During follow-up (median 5 years)
  - Normal renal function
  - No cardiac findings
  - 2 patients with newly diagnosed HTN

# Chronic End-Organ Complications




Figure 1. Sclerotic glomeruli and atrophic tubules with petechial hemorrhage




Figure 2. Hypertrophic myocytes

# **Mortality and Morbidities during Long-Term Follow-Up after Recovery from Thrombotic Thrombocytopenic Purpura (TTP)**

**Jessica A. Reese, Zayd L. Al-Nouri,  
Cassandra C. Deford, Lauren M. Stewart,  
Deirdra R. Terrell, Sara K. Vesely,  
Johanna A. Kremer Hovinga,  
Bernhard Lämmle, James N. George**

# Objective

- To document the long-term outcomes of patients following recovery from TTP associated with acquired severe ADAMTS13 deficiency (<10%)

# Methods: Follow-Up


- Telephone contact, 1-2 times per year
- Support group meetings, 3 times per year
- Clinic evaluation, once per year

# Results


- **57 survived their initial episode:**
  - **median age was 39 years (range 9-71)**
  - **45 (79%) were women**
  - **21 (37%) were black**




# Hypertension




# Diabetes



# Kidney Function



# Probability of Survival



# Probability of Survival

<b>Year(s) after initial episode</b>	<b>TTP Patients (95% CI)</b>	<b>Adjusted US Population</b>
<b>1</b>	<b>0.98 (0.87, 0.99)</b>	<b>0.997</b>
<b>5</b>	<b>0.90 (0.78, 0.96)</b>	<b>0.995</b>
<b>10</b>	<b>0.77 (0.59, 0.88)</b>	<b>0.992</b>
<b>15</b>	<b>0.67 (0.46, 0.82)</b>	<b>0.958</b>

# Attributed Causes of Death

- 1 – TTP relapse, confirmed by autopsy
- 1 – MI following recovery from TTP relapse; no TTP at autopsy
- 9 – Deaths with no evidence of TTP relapse
  - cardiovascular disease (4), ovarian cancer (1), sepsis (1), stroke (1), liver cirrhosis (1), intestinal hemorrhage (1)

# **Major Depression during Long-Term Follow-Up after Recovery from Thrombotic Thrombocytopenic Purpura (TTP)**

**Cassandra C. Deford, Lauren H. Schwartz,  
Jedidiah J. Perdue, Jessica A. Reese,  
Johanna A. Kremer Hovinga, Bernhard Lämmle,  
Lauren M. Stewart, Zayd L. Al-Nouri, Deirdra R. Terrell,  
James N. George, Sara K. Vesely**

# Methods: Depression Measures

- **Beck Depression Inventory-II (BDI-II) (2004-2011)**
  - **21 question screening measure for depression within previous 2 weeks**
- **In-person structured psychiatric interview (2011)**
  - **Definitive method for diagnosis of major depressive disorder (major depression)**



**47  
screened  
with BDI-II  
1 – 5 times  
2004 - 2011**

**15 (32%)  
severe depression  
≥ 1 time**

**7 (15%)  
moderate depression  
≥ 1 time**

**4 (8%)  
mild depression  
≥ 1 time**

**21 (45%)  
minimal or no  
depression at all times**


# Psychiatric Interviews: 2011



# Methods: Depression Measures

- **Patient Health Questionnaire-8 (PHQ-8) (2012)**
  - **8 question screening measure for depression within the previous 2 weeks**
  - **Used by the Behavioral Risk Factor Surveillance System (BRFSS)**
  - **Patients were screened 6.32 years (range, 1.79-16.12 years) after their initial episode of TTP**

# Major Depression: PHQ-8



# Conclusions

- **The prevalence of major depression is significantly increased in patients during long-term follow-up after recovery from TTP**
- **Recognition and appropriate management of major depression are critical components of the care of these patients**

# **The Oklahoma TTP-HUS Registry**

## **Risk of Recurrence with a Subsequent Pregnancy**

### **Oklahoma Registry:**

- 20 women with 35 subsequent pregnancies**

### **Systematic review of all published case reports:**

- 44 articles described 49 women with 70  
subsequent pregnancies**

***Transfusion* 2004; 44:1149  
(+ subsequent experience)**

# Recurrent TTP with a Subsequent Pregnancy

Category	Oklahoma	Literature
Congenital	-	12/13 (92%)
Acquired		
idiopathic	3/11 (27%)	11/18 (61%)
pregnancy	2/22 (9%)	18/39 (46%)
bloody diarrhea	0/2	-

# Pregnancy and Relapse Risk of TTP

- 5 patients with a previous history of TTP
  - 3/5 pregnancy-related (cases 1,2,and 4)
  - 1/5 multiple previous episodes (case 3)
  - 4 required PEX based upon pretreatment ADAMTS13 activity <5%

Table 3 ADAMTS 13 activity levels (%) throughout pregnancy for cases 1–5 by Collagen Binding Assay (NR:66–126%) or \*multimeric assay (NR:80–120%)

	Pre-pregnancy	10–16 weeks	20–26 weeks	Pre-delivery	6 weeks post partum
Case1	<5*	ND	ND	49*	ND
Case2	<5	5	16	30	<5
Case3	<5	<5	66	78	85
Case4	NA	<5	47	41	7
Case5	89*	90*	78*	93*	91*

Samples undertaken pre-exchange in cases 1–4 undergoing regular PEX. ND: not done. NA: not applicable.



## ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy

Patient	Circumstances	Week of gestation	ADAMTS13 activity (%)	Inhibitor level (BU)	Previous history of TTP
1	Pregnancy-related	22	<2.5%	1.5	No
2	Idiopathic	NA	<2.5%	57.6	No
3	Idiopathic	NA	<2.5%	5.2	No

Table II. ADAMTS 13 activity (inhibitor level in Bethesda units) in five pregnancies.

Patient	Pregnancy	Pre-pregnancy (1–11 months)	12–20 weeks	20 weeks- labour	Postpartum (4–6 weeks)	TTP/week of gestation
1	1	ND	ND	<2.5% (1.5)	<2.5% (3.2)	Yes/22
1	2	<2.5% (0.5)	<2.5% (0.7)	<2.5% (19.2)	<2.5% (0.5)	Yes/21
1	3	15.3% (0.5)*	14.8% (0.5)*	26% (0.5)*	<2.5% (2)	No/NA
2	1	<2.5% (22.4)	<2.5% (6.4)	<2.5% (2)	NA†	Yes/37
3	1	61.2% (0.5)	100% (0.5)	91.7% (0.5)	ND	No/NA

# Conclusions

- Significant increase in our knowledge of the long-term complications from a previous diagnosis of TTP
  - Greater number survivors
  - Patient support group
- Neurocognitive, vascular, and psychiatric complications are more common than recognized previously
- Increased awareness may lead to efforts to decrease the morbidity and mortality related to these chronic complications

